JP2020520926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520926A5 JP2020520926A5 JP2019563612A JP2019563612A JP2020520926A5 JP 2020520926 A5 JP2020520926 A5 JP 2020520926A5 JP 2019563612 A JP2019563612 A JP 2019563612A JP 2019563612 A JP2019563612 A JP 2019563612A JP 2020520926 A5 JP2020520926 A5 JP 2020520926A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- antibody
- antigen
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(***C(C)(CCC1)[C@@](CC2)C1(C)c1c2ccc(*)c1)(CCC1)C2C1(C)c1cc(*)ccc1CC2 Chemical compound CC(***C(C)(CCC1)[C@@](CC2)C1(C)c1c2ccc(*)c1)(CCC1)C2C1(C)c1cc(*)ccc1CC2 0.000 description 9
- MKBNLSBFSDMAPD-SUWXCJRCSA-N CC(CCC1)(C2[C@@]1(C)c1cc(NC)ccc1CC2)C(NC(C(C)(CCC1)C(CC2)C1(C)c1c2ccc(O)c1)=O)=O Chemical compound CC(CCC1)(C2[C@@]1(C)c1cc(NC)ccc1CC2)C(NC(C(C)(CCC1)C(CC2)C1(C)c1c2ccc(O)c1)=O)=O MKBNLSBFSDMAPD-SUWXCJRCSA-N 0.000 description 1
- JHXIOGXSUWJDGY-COLUFZAWSA-N CCNC(CC[C@@](C)(N1c(cccc2)c2C(C)=CC(/C=C\C)=C(C)C1)O)=O Chemical compound CCNC(CC[C@@](C)(N1c(cccc2)c2C(C)=CC(/C=C\C)=C(C)C1)O)=O JHXIOGXSUWJDGY-COLUFZAWSA-N 0.000 description 1
- RDRVUPKVKDZPLA-CHXXKMEHSA-N CC[C@H]([C@](C)(C1)[C@@H]1C([C@H](C(C)C)NC(CCOCCOCCOCCOCCNC(CCC(N(Cc1c(C)cccc1)C1=CCCC=C1)O)=O)=[O]=C)=O)C(NC1C=CC(C)CC1)=C Chemical compound CC[C@H]([C@](C)(C1)[C@@H]1C([C@H](C(C)C)NC(CCOCCOCCOCCOCCNC(CCC(N(Cc1c(C)cccc1)C1=CCCC=C1)O)=O)=[O]=C)=O)C(NC1C=CC(C)CC1)=C RDRVUPKVKDZPLA-CHXXKMEHSA-N 0.000 description 1
- WYSNDRNXTLKCCM-PHDIDXHHSA-N C[C@@H]([C@@H](C)N)C=C Chemical compound C[C@@H]([C@@H](C)N)C=C WYSNDRNXTLKCCM-PHDIDXHHSA-N 0.000 description 1
- BCPTYOQLOAOYPF-WSCPWJHYSA-N C[C@]1(C(CC2)C(CC(/C=N\C)=O)CCC1)C1=C2CCC(O)=C1 Chemical compound C[C@]1(C(CC2)C(CC(/C=N\C)=O)CCC1)C1=C2CCC(O)=C1 BCPTYOQLOAOYPF-WSCPWJHYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023077334A JP7843731B2 (ja) | 2017-05-18 | 2023-05-09 | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508327P | 2017-05-18 | 2017-05-18 | |
| US62/508,327 | 2017-05-18 | ||
| PCT/US2018/031910 WO2018213082A1 (en) | 2017-05-18 | 2018-05-09 | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077334A Division JP7843731B2 (ja) | 2017-05-18 | 2023-05-09 | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520926A JP2020520926A (ja) | 2020-07-16 |
| JP2020520926A5 true JP2020520926A5 (https=) | 2021-08-05 |
| JP7728636B2 JP7728636B2 (ja) | 2025-08-25 |
Family
ID=62245504
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563612A Active JP7728636B2 (ja) | 2017-05-18 | 2018-05-09 | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
| JP2023077334A Active JP7843731B2 (ja) | 2017-05-18 | 2023-05-09 | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077334A Active JP7843731B2 (ja) | 2017-05-18 | 2023-05-09 | ビス－オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180334426A1 (https=) |
| EP (1) | EP3625209A1 (https=) |
| JP (2) | JP7728636B2 (https=) |
| KR (2) | KR102713173B1 (https=) |
| CN (1) | CN111065622A (https=) |
| AU (1) | AU2018269568B2 (https=) |
| BR (1) | BR112019023990A2 (https=) |
| CA (2) | CA3247217A1 (https=) |
| CL (2) | CL2019003270A1 (https=) |
| CO (1) | CO2019014286A2 (https=) |
| EA (1) | EA201900562A1 (https=) |
| IL (1) | IL270595B2 (https=) |
| MA (1) | MA47392B1 (https=) |
| MX (1) | MX2019013693A (https=) |
| PH (1) | PH12019502576A1 (https=) |
| WO (1) | WO2018213082A1 (https=) |
| ZA (1) | ZA201907599B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3046537T3 (en) | 2016-11-08 | 2025-12-02 | Regeneron Pharma | Steroids and protein-conjugates thereof |
| WO2018213082A1 (en) * | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| MX2020004691A (es) * | 2017-11-07 | 2020-08-20 | Regeneron Pharma | Enlazadores hidrofilicos para conjugados anticuerpo-farmaco. |
| SG11202006510XA (en) | 2018-01-08 | 2020-08-28 | Regeneron Pharma | Steroids and antibody-conjugates thereof |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| IL283313B2 (en) | 2018-11-20 | 2025-08-01 | Regeneron Pharma | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
| BR112021013464A2 (pt) * | 2019-01-08 | 2021-09-21 | Regeneron Pharmaceuticals, Inc. | Ligantes sem traço e conjugados de proteína dos mesmos |
| CN115968304A (zh) | 2020-04-16 | 2023-04-14 | 瑞泽恩制药公司 | 狄尔斯-阿尔德缀合方法 |
| EP4172141A1 (en) * | 2020-06-26 | 2023-05-03 | Synaffix B.V. | Methods for the preparation of linker payload constructs |
| CN116390771A (zh) * | 2020-07-13 | 2023-07-04 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| US20220143194A1 (en) | 2020-11-10 | 2022-05-12 | Regeneron Pharmaceuticals, Inc. | Selenium antibody conjugates |
| CN112661783B (zh) * | 2020-12-28 | 2022-06-07 | 中国林业科学研究院林产化学工业研究所 | 一种硅氧烷二元松香基苯并环丁烯单体及其制备方法和应用 |
| CN115006390B (zh) * | 2022-06-27 | 2024-04-19 | 国药集团动物保健股份有限公司 | 一种病毒减毒制剂、其制备方法以及应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| WO2001041704A2 (en) * | 1999-12-13 | 2001-06-14 | Merck & Co., Inc. | Method for the prevention and/or treatment of atherosclerosis |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US6908934B2 (en) * | 2001-06-11 | 2005-06-21 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| US20060020036A1 (en) * | 2004-06-24 | 2006-01-26 | Luc Van Rompaey | Methods and compositions to promote bone homestasis |
| US7238791B1 (en) * | 2005-12-16 | 2007-07-03 | Roche Diagnostics Operations, Inc. | 6-monoacetylmorphine derivatives useful in immunoassay |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| US8993628B2 (en) | 2007-02-23 | 2015-03-31 | City Of Hope | Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2167963B1 (en) | 2007-05-23 | 2019-04-17 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| EA201390575A1 (ru) | 2010-10-29 | 2014-01-30 | Иммьюноджен, Инк. | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты |
| CN110078789A (zh) | 2011-05-27 | 2019-08-02 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| BR112014009070B1 (pt) | 2011-10-14 | 2021-11-23 | Medimmune Limited | Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| CN105814083A (zh) * | 2013-10-15 | 2016-07-27 | 加州生物医学研究所 | 嵌合抗原受体t细胞开关和其用途 |
| WO2015189478A1 (en) | 2014-06-13 | 2015-12-17 | Glykos Finland Oy | Payload-polymer-protein conjugates |
| US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| US20160324981A1 (en) * | 2015-05-08 | 2016-11-10 | The California Institute For Biomedical Research | Liver x receptor agonists and uses thereof |
| EP3419670A2 (en) | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| WO2018213082A1 (en) * | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
-
2018
- 2018-05-09 WO PCT/US2018/031910 patent/WO2018213082A1/en not_active Ceased
- 2018-05-09 CA CA3247217A patent/CA3247217A1/en active Pending
- 2018-05-09 JP JP2019563612A patent/JP7728636B2/ja active Active
- 2018-05-09 EP EP18727582.1A patent/EP3625209A1/en active Pending
- 2018-05-09 MA MA47392A patent/MA47392B1/fr unknown
- 2018-05-09 KR KR1020197036866A patent/KR102713173B1/ko active Active
- 2018-05-09 IL IL270595A patent/IL270595B2/en unknown
- 2018-05-09 EA EA201900562A patent/EA201900562A1/ru unknown
- 2018-05-09 MX MX2019013693A patent/MX2019013693A/es unknown
- 2018-05-09 AU AU2018269568A patent/AU2018269568B2/en active Active
- 2018-05-09 KR KR1020247032445A patent/KR20240150809A/ko active Pending
- 2018-05-09 CN CN201880047919.2A patent/CN111065622A/zh active Pending
- 2018-05-09 US US15/975,654 patent/US20180334426A1/en not_active Abandoned
- 2018-05-09 CA CA3063872A patent/CA3063872A1/en active Pending
- 2018-05-09 BR BR112019023990-1A patent/BR112019023990A2/pt unknown
-
2019
- 2019-11-14 CL CL2019003270A patent/CL2019003270A1/es unknown
- 2019-11-15 ZA ZA2019/07599A patent/ZA201907599B/en unknown
- 2019-11-18 PH PH12019502576A patent/PH12019502576A1/en unknown
- 2019-12-17 CO CONC2019/0014286A patent/CO2019014286A2/es unknown
-
2021
- 2021-10-05 US US17/494,762 patent/US12338199B2/en active Active
-
2023
- 2023-05-09 JP JP2023077334A patent/JP7843731B2/ja active Active
-
2024
- 2024-07-18 CL CL2024002173A patent/CL2024002173A1/es unknown
-
2025
- 2025-05-13 US US19/207,190 patent/US20250270163A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520926A5 (https=) | ||
| JP2012507522A5 (https=) | ||
| JP2833766B2 (ja) | アミノポリカルボン酸およびその誘導体 | |
| AU2018269568B2 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| JP2022507781A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| US12077554B2 (en) | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | |
| JP2021522276A5 (https=) | ||
| JP2022533069A5 (https=) | ||
| CN1396830A (zh) | 含有双膦酸盐的肠胃外药物组合物 | |
| EP3678700B1 (en) | Compounds for reducing the viscosity of biological formulations | |
| JP2007501862A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| JP2004507552A (ja) | 免疫調節剤としてのリン酸誘導体 | |
| CA2723440A1 (en) | Sulfobetaines for therapy | |
| CN102083773A (zh) | {f-19}标记的l-谷氨酸和l-谷氨酰胺衍生物(ⅲ)、其用途和制备方法 | |
| JP2024133626A (ja) | Ｐｅｇ化されたカルフィルゾミブ化合物の安定組成物 | |
| JP2020518571A5 (https=) | ||
| JP2010505865A5 (https=) | ||
| TW201726592A (zh) | 稠合三環γ－胺基酸衍生物、製備方法及其在醫藥上的應用 | |
| JP2024519536A5 (https=) | ||
| IL97902A (en) | Tetra-aza macrocycles processes for their preparation and their use in magnetic resonance imaging | |
| US20110300132A1 (en) | 4-aminoquinazoline prodrugs | |
| AU2018359224A1 (en) | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof | |
| CN1993115B (zh) | 2-氨基-1,3-丙二醇化合物的制剂 |